Allogene Therapeutics (ALLO) Competitors $1.11 -0.01 (-0.89%) Closing price 04:00 PM EasternExtended Trading$1.13 +0.02 (+1.80%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLO vs. SYRE, PRAX, CRMD, CRON, NUVB, VERV, VALN, MLYS, ATAI, and IOVAShould you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), CorMedix (CRMD), Cronos Group (CRON), Nuvation Bio (NUVB), Verve Therapeutics (VERV), Valneva (VALN), Mineralys Therapeutics (MLYS), atai Life Sciences (ATAI), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry. Allogene Therapeutics vs. Its Competitors Spyre Therapeutics Praxis Precision Medicines CorMedix Cronos Group Nuvation Bio Verve Therapeutics Valneva Mineralys Therapeutics atai Life Sciences Iovance Biotherapeutics Spyre Therapeutics (NASDAQ:SYRE) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Do institutionals & insiders have more ownership in SYRE or ALLO? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 15.4% of Spyre Therapeutics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to SYRE or ALLO? In the previous week, Spyre Therapeutics had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 7 mentions for Spyre Therapeutics and 3 mentions for Allogene Therapeutics. Spyre Therapeutics' average media sentiment score of 0.79 beat Allogene Therapeutics' score of 0.32 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, SYRE or ALLO? Spyre Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Is SYRE or ALLO more profitable? Allogene Therapeutics' return on equity of -55.99% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -71.30% -38.69% Allogene Therapeutics N/A -55.99%-42.75% Do analysts rate SYRE or ALLO? Spyre Therapeutics presently has a consensus price target of $53.40, suggesting a potential upside of 214.30%. Allogene Therapeutics has a consensus price target of $8.44, suggesting a potential upside of 660.76%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has stronger valuation and earnings, SYRE or ALLO? Spyre Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre TherapeuticsN/AN/A-$208.02M-$3.40-5.00Allogene TherapeuticsN/AN/A-$257.59M-$1.11-1.00 SummarySpyre Therapeutics beats Allogene Therapeutics on 8 of the 14 factors compared between the two stocks. Get Allogene Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLO vs. The Competition Export to ExcelMetricAllogene TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$246.29M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-1.0021.0283.0126.65Price / SalesN/A379.56503.03163.66Price / CashN/A43.5325.7028.92Price / Book0.728.1210.796.52Net Income-$257.59M-$53.35M$3.29B$266.21M7 Day Performance-5.93%0.05%0.02%-0.76%1 Month Performance0.91%7.08%7.06%3.83%1 Year Performance-56.98%11.92%50.09%24.39% Allogene Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLOAllogene Therapeutics2.1885 of 5 stars$1.11-0.9%$8.44+660.8%-55.4%$246.29MN/A-1.00310SYRESpyre Therapeutics2.7904 of 5 stars$16.58-4.6%$53.40+222.1%-36.8%$1.05BN/A-4.8873Insider TradePRAXPraxis Precision Medicines2.9425 of 5 stars$46.94-3.8%$85.88+82.9%-15.9%$1.03B$8.55M-3.82110News CoverageAnalyst ForecastCRMDCorMedix3.5444 of 5 stars$13.73+0.3%$16.71+21.7%+134.6%$1.02B$43.47M18.3130Positive NewsShort Interest ↑CRONCronos Group1.663 of 5 stars$2.60-0.2%N/A+12.9%$995.90M$117.61M51.90450NUVBNuvation Bio2.5163 of 5 stars$2.88-0.7%$7.33+154.6%+5.9%$992.59M$7.87M-4.5760News CoverageVERVVerve Therapeutics2.1755 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110VALNValneva2.0329 of 5 stars$9.43-19.0%$16.00+69.7%+20.8%$990.49M$183.52M-9.62700Short Interest ↑Gap DownHigh Trading VolumeMLYSMineralys Therapeutics1.8432 of 5 stars$14.74-1.0%$32.25+118.8%+144.8%$986.80MN/A-4.1428News CoverageAnalyst ForecastATAIatai Life Sciences3.5062 of 5 stars$4.74+3.7%$11.25+137.3%+270.5%$979.53M$310K-6.8780High Trading VolumeIOVAIovance Biotherapeutics4.3151 of 5 stars$2.53-5.9%$11.90+370.4%-79.6%$973.39M$164.07M-2.06500Positive News Related Companies and Tools Related Companies SYRE Competitors PRAX Competitors CRMD Competitors CRON Competitors NUVB Competitors VERV Competitors VALN Competitors MLYS Competitors ATAI Competitors IOVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLO) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts